LINNOVATEL: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN
administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered
intravenously.